NSETrading Window28 Sept 2026 · 28 Sept 2026, 02:20 pm
Trading Window
Cohance Lifesciences Limited · COHANCE
✦ AI Summary
Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will be closed for the Designated Persons and their immediate relatives from 1 October 2026 till 48 hours after the declaration of Unaudited Financial Results for the quarter and half year ending 30 September 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk2/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Cohance Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Attachments (1)
📄pdf
Download →
SUVENPHARMROHIT_28092026142039_Closure_of_Trading_Window_28Sept26.pdf
View document text
28 September 2026
To To
BSE Limited National Stock Exchange of India Limited
25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051
Scrip Code: 543064 Scrip Symbol: COHANCE
Dear Sir/Madam,
Sub: Intimation regarding Closure of Trading Window
Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, the
Trading Window for dealing in the securities of the Company will be closed for the Designated Persons and
their immediate relatives from 1 October 2026 and the same will remain closed till 48 hours after the
declaration of Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter
and half year ending 30 September 2026.
The date of the Board Meeting for consideration and approval of the Unaudited Financial Results for the
quarter and half year ending 30 September 2026 shall be informed in due course.
You are requested to take the above on record.
Thanking you.
Yours faithfully,
For Cohance Lifesciences Limited
(formerly, Suven Pharmaceuticals Limited)
Sisir K Mishra
Company Secretary and Compliance Officer